Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06474299 · ClinicalTrials.gov registry record · Phase 4
The Avenues Study: Dual Use Cessation
A Phase 4 study of Smoking Cessation and Electronic Cigarette Use, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT06474299: Recruiting Phase 4 study of Smoking Cessation and Electronic Cigarette Use, sponsored by University of Wisconsin, Madison.
NCT06474299 is a Phase 4 study of Smoking Cessation and Electronic Cigarette Use that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 500 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06474299, a Phase 4 study of Smoking Cessation and Electronic Cigarette Use, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.
Primary Outcome
52-week biochemically confirmed (anabasine\<2 ng/ml) 7-day point-prevalence abstinence from cigarettes
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Nicotine patch
- BEHAVIORAL Dual Focused Cessation Counseling
- BEHAVIORAL Smoking Focused Cessation Counseling
- OTHER Counseling Intensity: 1 Session
Study Locations (1)
Wisconsin
- University of Wisconsin-Madison School of Medicine and Public Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2028-07 |
| Phase | Phase 4 |
What NCT06474299 shows while recruiting
NCT06474299 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target.
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 5 interventions - of which Varenicline is the first listed.
NCT06474299 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06474299 about?
NCT06474299 is a clinical study titled "The Avenues Study: Dual Use Cessation". The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.
What is the current status of trial NCT06474299?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2024-09-24. Estimated completion is 2028-07.
What conditions does trial NCT06474299 study?
This clinical trial studies the following conditions: Smoking Cessation, Electronic Cigarette Use.
What interventions are being tested in trial NCT06474299?
The interventions under investigation include: Varenicline (DRUG), Nicotine patch (DRUG), Dual Focused Cessation Counseling (BEHAVIORAL), Smoking Focused Cessation Counseling (BEHAVIORAL), Counseling Intensity: 1 Session (OTHER).
Who is sponsoring clinical trial NCT06474299?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06474299 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06474299's enrollment target sits among peer trials
500 53rd of 188 higher than 132 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
-
Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI